#France #Bordeaux #Syensqo #Emulseo #Microfluidics

Syensqo and Emulseo's New Partnership

In a significant move for the healthcare industry, Syensqo, a preeminent specialty chemicals organization, is excited to announce its strategic collaboration with Emulseo, a French firm specializing in microfluidic technology formulations. This partnership aims to explore innovative applications within the rapidly expanding microfluidics market, focusing on improving healthcare solutions.

Microfluidics involves the manipulation of liquids at a microscopic level, an essential technique that has gained prominence in various sectors, especially in healthcare. The agreement will see Emulseo incorporate Syensqo’s state-of-the-art product, Galden® PFPE, into its Fluo-Oil product line. This collaboration is expected to provide healthcare clients with an essential tool for developing reliable and efficient microfluidic analyses through droplet-based techniques.

Droplet-based microfluidics is increasingly recognized for its accuracy and efficiency in handling minute quantities of liquids, making it a vital approach for studying DNA strands, cells, and pharmaceutical compounds. This technique has notable applications in diagnostics, including cancer detection via blood samples and rapid COVID-19 testing through digital PCR. The advanced capabilities provided by Syensqo's Galden® PFPE will undoubtedly enhance the performance and reliability of these crucial analyses.

Galden® PFPE presents unique properties, including its chemical inertness, low viscosity, and optical transparency, which are deemed optimal for microfluidic systems. According to Peter Browning, President of the Specialty Polymers Global business unit at Syensqo, “We are thrilled to partner with Emulseo and bring our Galden® PFPE to the forefront of microfluidics technology. This collaboration emphasizes our dedication to innovation, extending the applications of our materials to foster advancements in healthcare, such as improving cancer detection and accelerating vaccine development.”

Florine Maes, CEO of Emulseo, expressed enthusiasm for the partnership, emphasizing their eagerness to join forces with a reputable industry leader. She stated, “As a young and innovative company, Emulseo is proud to partner with Syensqo, focusing on supporting innovation and contributing to the development of advanced technologies within the health sector. Combining our expertise with Syensqo's high-performance chemicals allows us to enhance our product offerings for our global scientific and industrial customers.”

This partnership marks a pivotal moment in the synergy between specialty chemicals and healthcare innovation, setting the stage for groundbreaking developments in microfluidic technologies that can significantly improve patient outcomes and treatment precision around the world. As both companies look forward to leveraging their strengths, the healthcare sector can anticipate exciting advancements that will emerge from this collaboration.

Overall, Syensqo and Emulseo's strategic alliance is poised to make a substantial impact on future medical studies and applications, demonstrating the potential of combining chemistry and technology in improving human health.